Overall, AXL IC-negative patients had shorter OS (P = 0.054) and PFS (P = 0.044, Figure 2F/Supplementary Figure 2D) and similar results were observed for patients with total IC<2% (Supplementary Table 2), indicating that the presence of tumor-infiltrating immune cells, whether measured via simple morphological assessment or staining of the AXL+ immune-subset, associated with improved outcomes. This evidence concerns the gene AXL and neoplasm.